Arthur Μ. Krieg

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial”.

Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial

Cancer Cell(2024)10.1016/j.ccell.2024.10.007

N/A

1.3DataRank · unranked

59 citations

Robert M. Morrison, Amiran Dzutsev, Arivarasan Karunamurthy, Joë-Marc Chauvin, F. Amatore +48 more

PD-1 and Tim-3 Regulate the Expansion of Tumor Antigen-Specific CD8+ T Cells Induced by Melanoma Vaccines

UNC Libraries(2020)10.17615/nf2z-7x04

N/A

0DataRank · unranked

1 citations

Ahmad A. Tarhini, Joe Marc Chauvin, Stergios J. Moschos, Ornella Pagliano, Cindy Sander +12 more

605 Neoadjuvant vidutolimod (vidu) and nivolumab (nivo) results in MPR and immune activation in high-risk resectable melanoma (MEL): final phase II clinical trial results

Regular and Young Investigator Award Abstracts(2022)10.1136/jitc-2022-sitc2022.0605

N/A

0DataRank · unranked

4 citations

Joë-Marc Chauvin, Robert Morrison, Yulong Bai, Jie Sun, Hong Wang +22 more

Neoadjuvant Vidutolimod and Nivolumab in High-Risk Resectable Melanoma

Research Square(2022)10.21203/rs.3.rs-2235839/v1

N/A

0DataRank · unranked

1 citations

Arivarasan Karunamurthy, Joë-Marc Chauvin, Robert M. Morrison, Yulong Bai, Jie Sun +40 more